Works Cited

1. Blancou J, Meslin FX. Brief review of the history of zoonoses. Rev Sci Tech. 2000;19(1):15-22.

2. Uppsala Universitet. Systema Naturae: An Epoch-Making Book. Available at http://www2.linnaeus.uu.se/online/animal/1_1.html. Last accessed March 28, 2017.

3. Berger D. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 1: ancient times through the 19th century. MLO Med Lab Obs. 1999;31(7):28-30, 32, 34-40.

4. Medicine Net. Definition of Koch's Postulates. Available at http://www.medicinenet.com/script/main/art.asp?articlekey=7105. Last accessed March 28, 2017.

5. Berger D. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 2: laboratory science and professional certification in the 20th century. MLO Med Lab Obs. 1999;31(8):32-34, 36, 38.

6. Centers for Disease Control and Prevention. Eastern equine encephalitis—Florida, eastern United States, 1991. MMWR. 1991;40(31):533-535.

7. Burroughs T, Knobler S, Lederberg J (eds). The Emergence of Zoonotic Diseases: Understanding the Impact on Animal and Human Health. Washington, DC: National Academy Press; 2002.

8. Gilbert AT, Petersen BW, Recuenco S, et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. Am J Trop Med Hyg. 2012;87(2):206-215.

9. Sanchez A, Ksiazek TG, Rollin PE, et al. Reemergence of Ebola virus in Africa. Emerg Infect Dis. 1995;1(3):96-97.

10. Centers for Disease Control and Prevention. About Parasites. Available at https://www.cdc.gov/parasites/about.html. Last accessed March 28, 2017.

11. Horton HH, Misrahi JJ, Matthews GW, Kocher PL. Critical biological agents: disease reporting as a tool for determining bioterrorism preparedness. J Law Med Ethics. 2002;30(2):262-266.

12. Heymann DL (ed). Control of Communicable Diseases Manual. 20th ed. Washington, DC: World Health Organization/American Public Health Association; 2014.

13. Koehsler M, Walochnik J, Georgopoulos M, et al. Linguatula serrata tongue worm in human eye, Austria. Emerg Infect Dis. 2011;17(5).

14. Centers for Disease Control and Prevention. Laboratory Identification of Parasitic Diseases of Public Health Concern: Taeniasis. Available at https://www.cdc.gov/dpdx/taeniasis/index.html. Last accessed March 28, 2017.

15. Hugh-Jones ME, Hubbert WT, Hagstad HV. Zoonoses: Recognition, Control and Prevention. Ames, IA: University of Iowa Press; 1995.

16. Huff JL, Eberle R, Capitanio J, Zhou SS, Barry PA. Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol. 2003;84(Pt 1):83-92.

17. National Institute of Allergy and Infectious Diseases. A History of Lyme Disease, Symptoms, Diagnosis, Treatment, and Prevention. Available at https://www.niaid.nih.gov/diseases-conditions/lyme-disease. Last accessed March 28, 2017.

18. Centers for Disease Control and Prevention. Lyme Disease Data. Available at https://www.cdc.gov/lyme/stats/index.html. Last accessed March 28, 2017.

19. Grier T. Will There Ever Be An Accurate Test for Lyme Disease? Available at http://owndoc.com/pdf/when-accurate-lyme-tests.pdf. Last accessed March 28, 2017.

20. Lin T, Oliver JH Jr, Gao L, Kollars TM Jr, Clark KL. Genetic heterogeneity of Borrelia burgdorferi sensu lato in the southern United States based on restriction fragment length polymorphism and sequence analysis. J Clin Microbiol. 2001;39(7):2500-2507.

21. Humane Society of the United States. Lyme Disease. Available at http://www.humanesociety.org/animals/resources/facts/lyme_disease.html. Last accessed March 28, 2017.

22. Godin AJ. Wild Mammals of New England. Baltimore, MD: Johns Hopkins University Press; 1977.

23. Steere AC. A 58-year old man with a diagnosis of chronic Lyme disease. JAMA. 2002;288(8):1002-1010.

24. Spielman A. Host Abundance and Transmission of Ixodes-Borne Zoonoses. Cambridge, MA: Harvard University Press; 1994.

25. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004;113(8):1093-1101.

26. Depietropaolo DL, Powers JH, Gill JM. Diagnosis of Lyme disease. Am Fam Physician. 2005;72(2):297-304.

27. Steere AC, McHugh G, Suarez C, Hoitt J, Damle N, Sikland VK. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis. 2003;36(8):1078-1081.

28. Centers for Disease Control and Prevention. Ehrlichiosis. Available at https://www.cdc.gov/ehrlichiosis. Last accessed March 28, 2017.

29. Telford SR 3rd, Pollack RJ, Spielman A. Emerging vector-borne infections. Infect Dis Clin North Am. 1991;5(1):7-17.

30. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med. 1988;319(22):1441-1446.

31. IgeneX, Inc. Reference Laboratory Manual. Palo Alto, CA: IgeneX, Inc.; 1998: 1-17.

32. Centers for Disease Control and Prevention. Notice to readers: recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR. 1995;44(31):590-591.

33. Centers for Disease Control and Prevention. Notice to readers: caution regarding testing for Lyme disease. MMWR. 2005;54(5):125.

34. Meyerhoff JO. Lyme Disease. Available at http://emedicine.medscape.com/article/330178-overview. Last accessed March 28, 2017.

35. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135.

36. Centers for Disease Control and Prevention. West Nile Virus. Available at https://www.cdc.gov/westnile/index.html. Last accessed March 28, 2017.

37. Centers for Disease Control and Prevention. Lyme Disease Vaccination. Available at https://www.cdc.gov/lyme/prev/vaccine.html. Last accessed March 28, 2017.

38. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.

39. Centers for Disease Control and Prevention. Key Facts about Tularemia. Available at https://emergency.cdc.gov/agent/tularemia/facts.asp. Last accessed March 28, 2017.

40. Bratton RL, Corey R. Tick-borne disease. Am Fam Physician. 2005;71(12):2323-2330.

41. Cleveland KO. Tularemia. Available at http://emedicine.medscape.com/article/230923-overview#a0156. Last accessed March 28, 2017.

42. New York City Department of Health and Mental Hygiene. Tularemia. Available at https://www1.nyc.gov/site/doh/health/emergency-preparedness/emergencies-biological-tularemia.page. Last accessed March 28, 2017.

43. Centers for Disease Control and Prevention. Tularemia associated with a hamster bite—Colorado, 2004. MMWR. 2005;53(51):1202-1203.

44. Yuen JC, Malotky MV. Francisella tularensis osteomyelitis of the hand following a cat bite: a case of clinical suspicion. Plast Reconstr Surg. 2011;128(1):37e-39e.

45. Weinstein RA, Singh K. Laboratory-acquired infections. Clin Infect Dis. 2009;49(1):142-147.

46. LexiComp Online. Available at http://online.lexi.com. Last accessed March 28, 2017.

47. Reed DS, Smith LP, Cole KS, Santiago AE, Mann BJ, Barry EM. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Am Soc Microbiol. 2014;82(5):2098-2105.

48. Centers for Disease Control and Prevention. Rocky Mountain Spotted Fever (RMSF). Available at https://www.cdc.gov/rmsf/index.html. Last accessed March 28, 2017.

49. Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med. 2005;353(6):587-594.

50. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;24(2):78-85.

51. Western KA, Benson GD, Gleason NN, Healy GR, Schultz MG. Babesiosis in a Massachusetts resident. N Engl J Med. 1970;283(16):854-856.

52. Centers for Disease Control and Prevention. Parasites: Babesiosis. Available at https://www.cdc.gov/parasites/babesiosis/health_professionals/index.html Last accessed March 28, 2017.

53. Pritt BS, Sloan LM, Hoang DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med. 2011;365(5):422-429.

54. New York State Department of Health. Anaplasmosis and Ehrlichiosis: Tick-Borne Bacterial Infections. Available at https://www.health.ny.gov/diseases/communicable/ehrlichiosis/fact_sheet.htm. Last accessed March 28, 2017.

55. Pastula DM, Turabelidze G, Yates KF. Notes from the field: Heartland virus disease—United States, 2012–2013. MMWR. 2014;63(12):270-271.

56. Petersen LR, Marfin AA, Gubler DJ. West Nile virus. JAMA. 2003;290(4):524-528.

57. Centers for Disease Control and Prevention. West Nile Virus in the United States: Guidelines for Surveillance, Prevention, and Control. Available at http://www.cdc.gov/westnile/resources/pdfs/wnvGuidelines.pdf. Last accessed March 28, 2017.

58. Centers for Disease Control and Prevention. West Nile Virus: Final Annual Maps and Data for 1999–2015. Available at https://www.cdc.gov/westnile/statsmaps/finalmapsdata/index.html. Last accessed March 28, 2017.

59. Scherret JH, Poidinger M, Mackenzie JS, et al. The relationships between West Nile and Kunjin viruses. Emerg Infect Dis. 2001;7(4):697-705.

60. Centers for Disease Control and Prevention. West Nile virus activity: Eastern United States, 2001. MMWR. 2001;50(29):617-619.

61. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis. 2002;2(9):519-529.

62. Klenk K, Snow J, Morgan K, et al. Alligators as West Nile virus amplifiers. Emerg Infect Dis. 2004;10(12):2150-2155.

63. Centers for Disease Control and Prevention. Update: West Nile virus activity—Northeastern United States, 2000. MMWR. 2000;49(36):820-822.

64. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137(3):173-179.

65. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4):511-515.

66. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174-1179.

67. Salinas JD Jr. West Nile Virus. Available at http://emedicine.medscape.com/article/312210-overview. Last accessed April 13, 2017.

68. Nasci RS, Wirtz RA, Brogdon WG. Protection against mosquitoes, ticks, and other insects and arthropods. In: CDC's Health Information for International Travel: 2016 (Yellow Book). New York, NY: Oxford University Press; 2015.

69. National Institutes for Health. NIH-Funded Vaccine for West Nile Virus Enters Human Clinical Trials. Available at https://www.nih.gov/news-events/news-releases/nih-funded-vaccine-west-nile-virus-enters-human-clinical-trials. Last accessed April 13, 2017.

70. Centers for Disease Control and Prevention. Rabies: Transmission. Available at https://www.cdc.gov/rabies/transmission/index.html. Last accessed April 13, 2017.

71. Centers for Disease Control and Prevention. Is Rabies In Your State? Available at https://www.cdc.gov/rabies/location/usa/surveillance. Last accessed April 13, 2017.

72. Centers for Disease Control and Prevention. Human rabies prevention—United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48(RR-1):1-21.

73. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients.N Engl J Med. 2005;352(11):1103-1111.

74. Monroe BP, Yager P, Blanton J, et al. Rabies surveillance in the United States during 2014. J Am Vet Med Assoc. 2016;248(7):777-788.

75. Wilde H, Briggs DJ, Meslin FX, Hemachttdha T, Sitprija V. Rabies update for travel medicine advisors. Clin Infect Dis. 2003;37(1):96-100.

76. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60-63.

77. World Health Organization. Rabies. Available at http://www.who.int/rabies/en/. Last accessed April 13, 2017.

78. Centers for Disease Control and Prevention. Human death associated with bat rabies—California, 2003. MMWR. 2004;53(2):33-35.

79. World Health Organization. Administration of Rabies Immunoglobulin. Available at http://www.who.int/rabies/human/adminimmuno/en/. Last accessed April 13, 2017.

80. Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2010;59(RR2):1-9.

81. Centers for Disease Control and Prevention. Recovery of a patient from clinical rabies—Wisconsin, 2004. MMWR. 2004;53(50):1171-1173.

82. Medical College of Wisconsin. Rabies. Available at http://www.mcw.edu/rabies. Last accessed April 13, 2017.

83. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2008;57(RR3):1-26, 28.

84. Centers for Disease Control and Prevention. Compendium of animal rabies prevention and control, 2005. MMWR. 2005;54(RR03):1-8.

85. World Health Organization. Rabies vaccines: WHO position paper—recommendations. Vaccine. 2010;28(44):7140-7142.

86. Olsen CW. Influenza: pigs, people and public health. National Pork Board: Public Health Fact Sheet. 2004;2(6):1-3.

87. Centers for Disease Control and Prevention. Transmission of Influenza A Viruses between Animals and People. Available at https://www.cdc.gov/flu/avianflu/virus-transmission.htm. Last accessed April 13, 2017.

88. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO, 2003–Available at http://www.who.int/influenza/human_animal_interface/EN_GIP_20160404cumulativenumberH5N1cases.pdf. Last accessed April 13, 2017.

89. Centers for Disease Control and Prevention. Avian Influenza A Virus Infections in Humans. Available at https://www.cdc.gov/flu/avianflu/avian-in-humans.htm. Last accessed April 13, 2017.

90. World Health Organization. WHO Risk Assessment of Human Infection with Avian Influenza A (H7N9) Virus. Available at http://www.who.int/influenza/human_animal_interface/influenza_h7n9/en/. Last accessed April 13, 2017.

91. World Health Organization. Avian Influenza: Assessing the Pandemic Threat. Available at http://whqlibdoc.who.int/hq/2005/WHO_CDS_2005.29.pdf. Last accessed April 13, 2017.

92. Centers for Disease Control and Prevention. Public Health Threat of Highly Pathogenic Avian Influenza A (H5N1) Virus. Available at https://www.cdc.gov/flu/avianflu/h5n1-threat.htm. Last accessed April 13, 2017.

93. World Health Organization. Avian Influenza: Situation in Indonesia: Update. Available at http://www.who.int/csr/don/2012_08_10b/en/. Last accessed April 13, 2017.

94. Centers for Disease Control and Prevention. Avian Influenza in Birds. Available at https://www.cdc.gov/flu/avianflu/avian-in-birds.htm. Last accessed April 13, 2017.

95. Hitt E. Avian Flu: What Clinicians Need to Know. Available at http://www.medscape.com/viewarticle/468007. Last accessed April 13, 2017.

96. U.S. Department of Agriculture. Avian Influenza: Low Pathogenic H5N1 vs. Highly Pathogenic H5N1: Latest Update. Available at https://www.plano.gov/DocumentCenter/View/25. Last accessed April 13, 2017.

97. World Health Organization. Frequently Asked Questions on Human Infection Caused by the Avian Influenza A(H7N9) Virus. Available at http://www.who.int/influenza/human_animal_interface/faq_H7N9/en/. Last accessed April 13, 2017.

98. Centers for Disease Control and Prevention. Update: influenza activity, U.S. 2003–2004 season. MMWR. 2004;53(13):284-287.

99. Li C, Hatta M, Nidom CA, et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci U S A. 2010;107(10):4687-4692.

100. World Health Organization. H5N1 Highly Pathogenic Avian Influenza: Timeline of Major Events. Available at http://www.who.int/entity/influenza/human_animal_interface/H5N1_avian_influenza_update20141204.pdf?ua=1. Last accessed April 13, 2017.

101. Centers for Disease Control and Prevention. Outbreaks of Avian Influenza in North America. Available at https://www.cdc.gov/flu/avianflu/outbreaks.htm. Last accessed April 13, 2017.

102. Centers for Disease Control and Prevention. Influenza Type A Viruses. Available at https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm. Last accessed April 13, 2017.

103. Centers for Disease Control and Prevention. Prevention and Treatment of Avian Influenza A Viruses in People. Available at https://www.cdc.gov/flu/avianflu/prevention.htm. Last accessed April 13, 2017.

104. Kayali G, Kandeil A, El-Shesheny R, et al. Avian influenza A(H5N1) virus in Egypt. Emerg Infect Dis. 2016;22(3).

105. Crispin SW, Cohen M, Mapes T. Bird-flu outbreak revives concerns stirred by SARS. Wall St J. January 28, 2004:A1.

106. National Institutes of Health. NIH Scientists Target Future Pandemic Strains of H5N1 Avian Influenza. Available at https://www.nih.gov/news-events/news-releases/nih-scientists-target-future-pandemic-strains-h5n1-avian-influenza. Last accessed April 13, 2017.

107. Gamblin SJ, Haire LF, Russell RJ, et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science. 2004;303(5665):1838-1842.

108. Centers for Disease Control and Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone high-dose) and guidance for use—United States, 2010. MMWR. 2010;59(16):485-486.

109. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004;363(9409):587-593.

110. World Health Organization. WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus. Available at http://whqlibdoc.who.int/hq/2006/WHO_PSM_PAR_2006.6_eng.pdf. Last accessed April 13, 2017.

111. Centers for Disease Control and Prevention. Guidelines and Recommendations: Interim Guidance about Avian Influenza (H5N1) for U.S. Citizens Living Abroad. Available at https://wwwnc.cdc.gov/travel/page/avian-flu-americans-abroad. Last accessed April 13, 2017.

112. Centers for Disease Control and Prevention. Archived: Interim Guidance for Airline Flight Crews and Persons Meeting Passengers Arriving from Areas with Avian Influenza (Updated). Available at https://wwwnc.cdc.gov/travel/page/avian-flu-arriving-from-areas. Last accessed April 13, 2017.

113. Centers for Disease Control and Prevention. Malaria Diagnosis (United States). Available at https://www.cdc.gov/malaria/diagnosis_treatment/diagnosis.html. Last accessed April 13, 2017.

114. World Health Organization. Availability of New Recombinant H5N1 Vaccine Virus. Available at http://www.who.int/influenza/vaccines/virus/H5N1virus26May/en/. Last accessed April 13, 2017.

116. Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26(3):476-492.

117. U.S. Food and Drug Administration. H5N1 Influenza Virus Vaccine, manufactured by Sanofi Pasteur, Inc. Questions and Answers. Available at https://www.fda.gov/biologicsbloodvaccines/vaccines/questionsaboutvaccines/ucm080753.htm. Last accessed April 13, 2017.

118. Science Daily. Universal Influenza Vaccine Tested Successfully in Humans. Available at https://www.sciencedaily.com/releases/2008/01/080124185522.htm. Last accessed April 13, 2017.

119. Centers for Disease Control and Prevention. Information on Swine Influenza/Variant Influenza Viruses. Available at https://www.cdc.gov/flu/swineflu/. Last accessed April 13, 2017.

120. World Health Organization. Avian Influenza Update: Implications of H5N1 Infections in Pigs in China. Available at http://www.who.int/csr/don/2004_08_25/en/. Last accessed April 13, 2017.

121. World Health Organization. Pandemic (H1N1) 2009: Frequently Asked Questions. Available at http://www.who.int/csr/disease/swineflu/frequently_asked_questions/en/. Last accessed April 13, 2017.

122. Centers for Disease Control and Prevention. 2009 H1N1 Flu ("Swine Flu") and You. Available at https://www.cdc.gov/h1n1flu/qa.htm. Last accessed April 13, 2017.

123. Centers for Disease Control and Prevention. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009–2010 Season. Available at https://www.cdc.gov/h1n1flu/recommendations.htm. Last accessed April 13, 2017.

124. World Health Organization. H1N1 in Post-Pandemic Period. Available at http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/. Last accessed April 13, 2017.

125. Fiore AE, Uyeki TM, Broder KM, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59(RR8):1-62.

126. Centers for Disease Control and Prevention. Interim Guidance on Infection Control Measures for 2009 H1N1 Influenza in Healthcare Settings, Including Protection of Healthcare Personnel. Available at https://www.cdc.gov/h1n1flu/guidelines_infection_control.htm. Last accessed April 13, 2017.

127. California Department of Public Health. H1N1 Flu FAQs (Prevention). Available at http://www.cdph.ca.gov/HealthInfo/h1n1flufaqs/Pages/H1N1fluFAQs-03-Prevention.aspx. Last accessed April 13, 2017.

128. Lau JTF, Griffiths S, Choi K-C, Lin C. Prevalence of preventive behaviors and associated factors during early phase of the H1N1 influenza epidemic. Am J Infect Control. 2010;38(5):374-380.

129. Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2009;58(RR10):1-8.

130. American Lung Association. Diagnosing and Treating Hantavirus Pulmonary Syndrome (HPS). Available at http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/hantavirus-pulmonary-syndrome-hps/diagnosing-treating-hps.html. Last accessed April 13, 2017.

131. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65(5):1-54.

132. California Department of Public Health. H1N1 Flu. Available at http://www.cdph.ca.gov/HealthInfo/discond/Pages/H1N1Home.aspx. Last accessed April 13, 2017.

133. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2008;57(RR7):1-60.

134. Centers for Disease Control and Prevention. Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009–April 10, 2010. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm. Last accessed April 13, 2017.

135. World Health Organization. Fact Sheet No. 117: Dengue and Severe Dengue. Available at http://www.who.int/mediacentre/factsheets/fs117/en/. Last accessed April 13, 2017.

136. U.S. Food and Drug Administration. FDA Public Health Alert: Potential Medication Errors with Tamiflu for Oral Suspension. Available at https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm183649.htm. Last accessed April 13, 2017.

137. Centers for Disease Control and Prevention. Antiviral Drug Resistance among Influenza Viruses. Available at https://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm. Last accessed April 13, 2017.

138. Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2010;54(1):126-133.

139. U.S. Food and Drug Administration. Emergency Use Authorization of Peramivir IV: Fact Sheet for Health Care Providers. Available at https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf. Last accessed April 13, 2017.

140. U.S. Food and Drug Administration. RIPAVAB (Peramivir Injection), for Intravenous Use. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf. Last accessed April 13, 2017.

141. Centers for Disease Control and Prevention. Reported Cases of HPS. Available at https://www.cdc.gov/hantavirus/surveillance/index.html. Last accessed April 13, 2017.

142. Centers for Disease Control and Prevention. Hantavirus. Available at https://www.cdc.gov/hantavirus. Last accessed April 13, 2017.

143. Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome—Vermont, 2000. MMWR. 2001;50(28):603-605.

144. Centers for Disease Control and Prevention. Hantavirus: Technical/Clinical Information. Available at https://www.cdc.gov/hantavirus/technical/index.html. Last accessed April 13, 2017.

145. Centers for Disease Control and Prevention. Lymphocytic Choriomeningitis: Fact Sheet. Available at https://www.cdc.gov/vhf/lcm/pdf/factsheet.pdf. Last accessed April 13, 2017.

146. Centers for Disease Control and Prevention. Update: interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated with pet rodents. MMWR. 2005;54(Dispatch):1-3.

147. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235-2249.

148. Centers for Disease Control and Prevention. Variant Creutzfeldt-Jakob Disease. Available at https://www.cdc.gov/prions/vcjd/index.html. Last accessed April 13, 2017.

149. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis. 2001;7(1):6-16.

150. Takemura K, Kahdre M, Joseph D, Yousef A, Sreevatsan S. An overview of transmissible spongiform encephalopathies. Anim Health Res Rev. 2004;5(2):103-124.

151. Centers for Disease Control and Prevention. BSE in North America. Available at https://www.cdc.gov/prions/bse/bse-north-america.html. Last accessed April 13, 2017.

152. George LW. Diseases of the nervous system. In: Smith BP (ed). Large Animal Internal Medicine. 5th ed. St. Louis, MO: Mosby-Year Book, Inc.; 2014.

153. Collinge J. Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet. 1997;6(10):1699-1705.

154. Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: epidemiological studies on the origin. Veterinary Record. 1991;128:199-203.

155. Detwilder LA. Animal Transmissible Spongiform Encephalopathies (TSEs) and Their Impact on Animal and Human Health Worldwide. Yulee, FL: Proceedings of the American Association of Zoo Veterinarians; 1998.

156. Centers for Disease Control and Prevention. Investigation of progressive inflammatory neuropathy among swine slaughterhouse workers—Minnesota, 2007–2008. MMWR. 2008;57(5):1-3.

157. Lachance DH. Outbreak of immune polyradiculoneuropathy in workers exposed to porcine neural tissue. Abstract LBS.001. Academy of Neurology 60th Annual Meeting. Presented April 16, 2008.

158. Krause EZ. Variant Cruetzfeldt-Jakob Disease and Bovine Spongiform Encephalopathy. Available at http://emedicine.medscape.com/article/1169688-overview. Last accessed April 13, 2017.

159. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. Am J Neuroradiol. 2003;24(8):1560-1569.

160. Centers for Disease Control and Prevention. Variant Creutzfeldt-Jakob Disease: Risk for Travelers. Available at https://www.cdc.gov/prions/vcjd/risk-travelers.html. Last accessed April 13, 2017.

161. Amaral L, Kristiansen JE. Phenothiazines: potential management of Creutzfeldt-Jakob disease and its variant. Int J Antimicrob Agents. 2001;18(5):411-417.

162. Centers for Disease Control and Prevention. Dengue: Epidemiology. Available at https://www.cdc.gov/dengue/epidemiology/index.html. Last accessed April 13, 2017.

163. Tomashek KM, Sharp TM, Margolis HS. Dengue. In: CDC's Health Information for International Travel: 2016 (Yellow Book). New York, NY: Oxford University Press; 2015.

164. Centers for Disease Control and Prevention. Dengue: Entomology and Ecology. Available at https://www.cdc.gov/Dengue/entomologyEcology/index.html. Last accessed April 13, 2017.

165. Centers for Disease Control and Prevention. Dengue: Symptoms and What To Do If You Think You Have Dengue. Available at https://www.cdc.gov/dengue/symptoms. Last accessed April 13, 2017.

166. Wiwanitkit V. The importance of accurate diagnosis of dengue fever. Future Virology. 2012;7(1):53-62.

167. Centers for Disease Control and Prevention. Toxoplasmosis (Toxoplasma Infection). Available at https://www.cdc.gov/parasites/toxoplasmosis. Last accessed April 13, 2017.

168. Foreyt WJ (ed). Veterinary Parasitology: Reference Manual. 5th ed. Ames, IA: Blackwell Publishing Professional; 2001.

169. Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010;26(4):190-196.

170. Kravetz JD, Federman DG. Cat-associated zoonoses. Arch Intern Med. 2002;162(17):1945-1952.

171. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829-1833.

172. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. 2009;58(RR-4):1-207.

173. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR. 2009;58(RR-11):1-166.

174. Centers for Disease Control and Prevention. Giardia. Available at https://www.cdc.gov/parasites/giardia. Last accessed April 13, 2017.

175. Adam RD. Biology of Giardia lamblia. Clin Microbiol Rev. 2001;14(3):447-475.

176. Buret AG. Mechanisms of epithelial dysfunction in giardiasis. Gut. 2007;56(3):316-317.

177. Nazer H. Giardiasis. Available at http://emedicine.medscape.com/article/176718-overview. Last accessed April 13, 2017.

178. Minvielle MC, Molina NB, Polverino D, Basualdo JA. First genotyping of Giardia lamblia from human and animal feces in Argentina, South America. Mem Inst Oswaldo Cruz. 2008;103(1):98-103.

179. Praesertbun R, Sukthana Y, Popruk S. Realtime PCR: benefits for detection of mild and symptomatic Giardia infections. Trop Med Health. 2012;40(2):31-35.

180. Centers for Disease Control and Prevention. Cryptosporidium (Also Known As "Crypto"): A Guide to Commercially-Bottled Water and Other Beverages. Available at https://www.cdc.gov/parasites/crypto/gen_info/bottled.html. Last accessed April 13, 2017.

181. World Health Organization. Fact Sheet No. 94: Malaria. Available at http://www.who.int/mediacentre/factsheets/fs094/en/index.html. Last accessed April 13, 2017.

182. Centers for Disease Control and Prevention. Impact of Malaria. Available at https://www.cdc.gov/malaria/malaria_worldwide/impact.html. Last accessed April 13, 2017.

183. World Health Organization. World Malaria Report, 2016. Available at http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/. Last accessed April 13, 2017.

184. Centers for Disease Control and Prevention. Malaria Facts. Available at https://www.cdc.gov/malaria/about/facts.html. Last accessed April 13, 2017.

185. World Health Organization. Guidelines for the Treatment of Malaria. 3rd ed. Geneva: World Health Organization; 2015.

186. Centers for Disease Control and Prevention. Malaria: Disease. Available at https://www.cdc.gov/malaria/about/disease.html. Last accessed April 13, 2017.

187. Rubio JM, Buhigas I, Subirats M, Baquero M, Puente S, Benito A. Limited level of accuracy provided by available rapid diagnosis tests for malaria enhances the need for PCR-based reference laboratories. J Clin Microbiology. 2001;39(7):2736-2737.

188. Centers for Disease Control and Prevention. Treatment of Malaria (Guidelines for Clinicians). Available at https://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf. Last accessed April 13, 2017.

189. Centers for Disease Control and Prevention. Treatment of Malaria: Guidelines for Clinicians (United States). Available at https://www.cdc.gov/malaria/diagnosis_treatment/clinicians2.html. Last accessed April 13, 2017.

190. Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis. 2010;16(4):672-674.

191. Lo Re V III, Gluckman SJ. Prevention of malaria in travelers. Am Fam Phys. 2003;68(3):509-514.

192. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR. 2010;59(RR06):1-30.

193. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287(17):2236-2252.

194. Cunha BA. Anthrax. Available at http://emedicine.medscape.com/article/212127-overview. Last accessed April 13, 2017.

195. Centers for Disease Control and Prevention. Anthrax: Guidelines and Recommendations. Available at https://www.cdc.gov/anthrax/specificgroups/health-care-providers/index.html. Last accessed April 13, 2017.

196. Shadomy SV, Traxler RM, Marston CK. Infectious diseases related to travel: anthrax. In: CDC's Health Information for International Travel: 2016 (Yellow Book). New York, NY: Oxford University Press; 2015.

197. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2).

198. Withers MR (ed). Medical Management of Biological Casualties Handbook. 8th ed. Fort Detrick, MD: US Army Medical Research Institute of Infectious Diseases; 2014.

199. Jang KH, Nam S-J, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete. Angew Chem Int Ed Engl. 2013;52(30):7822-7824.

200. U.S. Food and Drug Administration. Vibrio vulnificus Health Education Kit Fact Sheet: Raw Oysters Contaminated with Vibrio vulnificus Can Cause Illness and Death. Available at https://www.fda.gov/Food/ResourcesForYou/healthEducators/ucm085365.htm. Last accessed April 13, 2017.

201. World Health Organization. Cholera. Available at http://www.who.int/mediacentre/factsheets/fs107/en. Last accessed April 13, 2017.

202. Centers for Disease Control and Prevention. Vibrio cholerae Infection: Treatment. Available at https://www.cdc.gov/cholera/treatment/index.html. Last accessed April 13, 2017.

203. U.S. Food and Drug Administration. FDA Approves Vaccine to Prevent Cholera for Travelers. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm506305.htm. Last accessed April 13, 2017.

204. Chan-Tack KM. Botulism. Available at http://emedicine.medscape.com/article/213311-overview. Last accessed April 13, 2017.

205. Centers for Disease Control and Prevention. Botulism. Available at https://www.cdc.gov/botulism. Last accessed April 13, 2017.

206. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA. 1997;278(5):433-435.

207. U.S. Food and Drug Administration. BAT (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) (Equine). Available at https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm345134.htm . Last accessed April 13, 2017.

208. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR. 2010;59(10):299.

209. Centers for Disease Control and Prevention. Botulism Manual. Available at https://www.cdc.gov/botulism/pdf/bot-manual.pdf. Last accessed April 13, 2017.

210. World Health Organization. Fact Sheet No. 139: Salmonella (Non-Typhoidal). Available at http://www.who.int/mediacentre/factsheets/fs139/en/. Last accessed April 13, 2017.

211. Centers for Disease Control and Prevention. Salmonellosis: Technical Information. Available at https://www.cdc.gov/salmonella/general/technical.html. Last accessed April 13, 2017.

212. Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev. 2012;11:CD001167.

213. Centers for Disease Control and Prevention. Healthy Pets Healthy People: Salmonella Infection. Available at https://www.cdc.gov/healthypets/diseases/salmonella.html. Last accessed April 13, 2017.

214. Centers for Disease Control and Prevention. What is Salmonellosis? Available at https://www.cdc.gov/salmonella/general/index.html. Last accessed April 13, 2017.

215. Cody SH, Abbott SL, Marfin AA, et al. Two outbreaks of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. 1999;281(19):1805-1810.

216. Bouza E, Sánchez-Carrillo C, Hernangómez S, González MJ. Laboratory-acquired brucellosis: a Spanish national survey. J Hosp Infect. Sep 2005;61(1):80-83.

217. U.S. Department of Agriculture. Brucellosis and Yellowstone Bison. Available at http://www.aphis.usda.gov/animal_health/animal_dis_spec/cattle/downloads/cattle-bison.pdf. Last accessed April 13, 2017.

218. Gerberding JL, Romero JM, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 34-2008: a 58-year-old woman with neck pain and fever. N Engl J Med. 2008;359(18):1942-1949.

219. Centers for Disease Control and Prevention. Brucellosis. Available at http://www.cdc.gov/brucellosis/. Last accessed April 13, 2017.

220. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;10:CD007179.

221. Lubani MM, Dudin KI, Sharda DC, Ndhar DS, Araj GF, Hafez HA, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989;8(2):75-78.

222. Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J. 2006;25(6):544-545.

223. Robichaud S, Libman M, Behr M, Rubin E. Prevention of laboratory-acquired brucellosis. Clin Infect Dis. 2004;38(12):e119-e122.

224. Northrop-Clewes CA, Shaw C. Parasites. Br Med Bull. 2000;56(1):193-208.

225. Centers for Disease Control and Prevention. Laboratory Identification of Parasitic Diseases of Public Health Concern: Trichinellosis. Available at https://www.cdc.gov/dpdx/trichinellosis/index.html. Last accessed April 13, 2017.

226. de Silva N, Guyatt H, Bundy D. Anthelmintics: a comparative review of their clinical pharmacology. Drugs. 1997;53(5):769-788.

227. Centers for Disease Control and Prevention. Dipylidium Infection (Also Known As Dog and Cat Flea Tapeworm). Available at https://www.cdc.gov/parasites/dipylidium/. Last accessed April 13, 2017.

228. Sun M. Dipylidiasis. Available at http://www.stanford.edu/class/humbio103/ParaSites2003/Dipylidiasis/index.htm. Last accessed April 13, 2017.

229. Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2010;(1):CD000215.

230. Tokyo Medical and Dental University. Anisakiasis. Available at http://www.tmd.ac.jp/med/mzoo/vlm/anisakiasis. Last accessed April 13, 2017.

231. Weir E. Sushi, nemotodes, and allergies. CMAJ. 2005;172(3):329.

232. Centers for Disease Control and Prevention. Anisakiasis. Available at https://www.cdc.gov/parasites/anisakiasis/. Last accessed April 13, 2017.

233. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax.Emerg Infect Dis. 2008;14(4).

234. U.S. Food and Drug Administration. FDA Approves Treatment for Inhalation Anthrax. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm. Last accessed April 13, 2017.

235. Centers for Disease Control and Prevention. New Lyme-Disease-Causing Bacteria Species Discovered. Available at https://www.cdc.gov/media/releases/2016/p0208-lyme-disease.html. Last accessed March 28, 2017.

236. Kirkpatrick BD, Whitehead SS, Pierce KK. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in human challenge model. Sci Transl Med. 2016;8(330):330.

237. Centers for Disease Control and Prevention. Multi-State Outbreak of Seoul Virus. Available at https://www.cdc.gov/hantavirus/outbreaks/seoul-virus/index.html. Last accessed April 13, 2017.

238. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Available at http://www.neurology.org/content/69/1/91.full. Last accessed March 28, 2017.

239. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134.

240. Centers for Disease Control and Prevention. Tularemia: Prevention. Available at https://www.cdc.gov/tularemia/prevention. Last accessed March 28, 2017.

241. ClinicalTrials.gov. Phase 1 Trial of Inactivated West Nile Virus Vaccine. Available at https://clinicaltrials.gov/ct2/show/NCT02337868. Last accessed April 13, 2017.

242. Centers for Disease Control and Prevention. Rabies Vaccine. Available at https://www.cdc.gov/rabies/medical_care/vaccine.html. Last accessed April 13, 2017.

243. Centers for Disease Control and Prevention. First Human Avian Influenza A (H5N1) Virus Infection Reported in Americas. Available at https://www.cdc.gov/flu/news/first-human-h5n1-americas.htm. Last accessed April 13, 2017.

244. World Health Organization. Human infection with avian influenza A(H7N9) virus—China. Available at http://www.who.int/csr/don/03-april-2017-ah7n9-china/en/. Last accessed April 13, 2017.

245. Centers for Disease Control and Prevention. Bird Infections with Highly-Pathogenic Avian Influenza A (H5N2), (H5N8), and (H5N1) Viruses: Recommendations for Human Health Investigations and Response. Available at https://emergency.cdc.gov/han/han00378.asp. Last accessed April 13, 2017.

246. U.S. Food and Drug Administration. Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. Available at https://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm074089.htm. Last accessed April 13, 2017.

247. World Organisation for Animal Health. Bovine Spongiform Encephalopathy (BSE): List of Bovine Spongiform Encephalopathy Risk Status of Member Countries. Available at http://www.oie.int/animal-health-in-the-world/official-disease-status/bse/list-of-bse-risk-status. Last accessed April 13, 2017.

248. California Department of Public Health. Infant Botulism Treatment and Prevention Program. Available at http://www.cdph.ca.gov/programs/ibtpp/Pages/default.aspx. Last accessed April 13, 2017.

249. McCarty CL, Angelo K, Beer KD, et al. Large outbreak of botulism associated with a church potluck meal—Ohio, 2015. MMWR. 2015;64(29):802-803.

250. John, DT, Petri WA. The intestinal nematodes. In: Markell and Voge's Medical Parasitology. 9th ed. St. Louis, MO: Saunders; 2013: 239-273.

251. Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009;15(9):1347-1350.

252. Fauci AS, Morens DM. Zika virus in the Americas: yet another arbovirus threat. N Engl J Med. 2016;374(7):601-604.

253. Oduyebo T, Igbinosa I, Petersen EE, et al. Update: interim guidance for health care providers caring for pregnant women with possible Zika virus exposure—United States, July 2016. MMWR. 2016;65(29):739-744.

254. Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR. 2016;65(21):543-546.

255. Centers for Disease Control and Prevention. Diagnostic Tests for Zika Virus. Available at https://www.cdc.gov/zika/hc-providers/types-of-tests.html. Last accessed April 13, 2017.

256. Centers for Disease Control and Prevention. Areas with Zika Virus: Case Counts in the U.S. Available at https://www.cdc.gov/zika/geo/united-states.html. Last accessed April 13, 2017.

257. Monaghan AJ, Morin CW, Steinhoff DF, et al. On the seasonal occurrence and abundance of the Zika virus vector mosquito Aedes aegypti in the contiguous United States. PLoS Curr. 2016;1.

258. Hills SL, Russell K, Hennessey M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—continental United States, 2016. MMWR. 2016;65(8):215-216.

259. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Zika Virus Epidemic in the Americas: Potential Association with Microcephaly and Guillain-Barré Syndrome. Available at http://ecdc.europa.eu/en/publications/Publications/zika-virus-americas-association-with-microcephaly-rapid-risk-assessment.pdf. Last accessed April 13, 2017.

260. U.S. Food and Drug Administration. FDA Advises Testing for Zika Virus in All Donated Blood and Blood Components in the US. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518218.htm. Last accessed April 13, 2017.

261. Oster AM, Russell K, Stryker JE, et al. Update: interim guidance for prevention of sexual transmission of Zika virus—United States, 2016. MMWR. 2016;65(12):323-325.

262. Russell PK. The Zika pandemic: a perfect storm? PLoS Negl Trop Dis. 2016;10(3):e0004589.

263. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016;374(16):1552-1563.

264. Brasil P, Pereira JP Jr, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro: preliminary report. Obstet Gynecol Surv. 2016;71(6):331-333.

265. Carteaux G, Maquart M, Bedet A, et al. Zika virus associated with meningoencephalitis. N Engl J Med. 2016;374(16):1595-1596.

266. Karimi O, Goorhuis A, Schinkel J, et al. Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. Lancet. 2016;387(10022):939-940.

267. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas: region of the Americas, May 2015–January 2016. MMWR. 2016;65(3):55-58.

268. U.S. Food and Drug Administration. First FDA-Approved Vaccine for the Prevention of Dengue Disease in Endemic Regions. Available at https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions. Last accessed June 7, 2019.

Evidence-Based Practice Recommendations Citations

1. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/49320. Last accessed April 14, 2017.

2. Broderick DF, Wippold FJ II, Cornelius RS, et al. ACR Appropriateness Criteria: Ataxia. Reston, VA: American College of Radiology; 2012. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/37932. Last accessed April 14, 2017.

3. Paquet C, Yudin MH, Infectious Disease Committee. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. 2013;35(1 eSuppl A):S1-S7. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/43843. Last accessed April 14, 2017.

4. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guidelines: Acute Diarrhea in Adults and Children: A Global Perspective. Milwaukee, WI: World Gastroenterology Organisation; 2012. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/47569. Last accessed April 14, 2017.


Copyright © 2017 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.